A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Public ClinicalTrials.gov record NCT02417064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.
Study identification
- NCT ID
- NCT02417064
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 346 participants
Conditions and interventions
Conditions
Interventions
- Esketamine Drug
- Placebo Drug
- Duloxetine (Oral Antidepressant) Drug
- Escitalopram (Oral antidepressant) Drug
- Sertraline (Oral Antidepressant) Drug
- Venlafaxine Extended Release (XR) (Oral Antidepressant) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2015
- Primary completion
- Feb 19, 2018
- Completion
- Feb 19, 2018
- Last update posted
- Apr 28, 2025
2015 – 2018
United States locations
- U.S. sites
- 37
- U.S. states
- 21
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Marcos | California | — | — |
| Not listed | San Rafael | California | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Hoffman Estates | Illinois | — | — |
| Not listed | Maywood | Illinois | — | — |
| Not listed | Schaumburg | Illinois | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Gaithersburg | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Quincy | Massachusetts | — | — |
| Not listed | Watertown | Massachusetts | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | O'Fallon | Missouri | — | — |
| Not listed | Saint Charles | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Media | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Lincoln | Rhode Island | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Woodstock | Vermont | — | — |
| Not listed | Bothell | Washington | — | — |
| Not listed | Middleton | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
Recently updated Treatment-resistant Depression trials
Other public records listing Treatment-resistant Depression. Sorted by last update posted; newest first. Not a recommendation.
- NCT06002204: Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression Active, not recruiting
- NCT03952962: Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression Recruiting
- NCT06480201: Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression Recruiting
- NCT05849402: Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder Active, not recruiting
- NCT05774665: Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression Active, not recruiting
- NCT07227103: A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02417064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02417064 live on ClinicalTrials.gov.